Advanced in Chronic Myelogenous Leukemia (CML)

Noam Benyamini

8, Ha'Aliya Street, 
Haifa, HA, IL 
Advanced in Chronic Myelogenous Leukemia (CML)
8, Ha'Aliya Street, 
Haifa, HA, IL 
OverviewLocationsClinical Research

Overview

Noam Benyamini practices in Haifa, Israel. Mr. Benyamini is rated as an Advanced expert by MediFind in the treatment of Chronic Myelogenous Leukemia (CML). His top areas of expertise are B-Cell Lymphoma, Chronic Myelogenous Leukemia (CML), Non-Hodgkin Lymphoma, Multiple Myeloma, and Bone Marrow Transplant.

His clinical research consists of co-authoring 41 peer reviewed articles and participating in 2 clinical trials. MediFind looks at clinical research from the past 15 years. In particular, he has co-authored 4 articles and participated in 1 clinical trial in the study of Chronic Myelogenous Leukemia (CML).

Gender
Male

Locations

8, Ha'Aliya Street, Haifa, HA 31096, Israel
Other Locations
6 Weizmann Street, Tel Aviv, TA 64239, Israel

Clinical Research

Clinical research consists of overseeing clinical studies of patients undergoing new treatments and therapies, and publishing articles in peer reviewed medical journals. Experts who actively participate in clinical research are generally at the forefront of the fields and aware of the most up-to-date advances in treatments for their patients.

2 Clinical Trials

A Phase 3 Randomized, Controlled, Open-label Study of Selinexor, Bortezomib, and Dexamethasone (SVd) Versus Bortezomib and Dexamethasone (Vd) in Patients With Relapsed or Refractory Multiple Myeloma (RRMM)
A Phase 3 Randomized, Controlled, Open-label Study of Selinexor, Bortezomib, and Dexamethasone (SVd) Versus Bortezomib and Dexamethasone (Vd) in Patients With Relapsed or Refractory Multiple Myeloma (RRMM)
Enrollment Status: Completed
Publish Date: August 21, 2024
Intervention Type: Drug
Study Drugs: Selinexor, Bortezomib, Dexamethasone
Study Phase: Phase 3
The Effect of Active Adherence-Encouraging Interventions on Adherence to Tyrosine Kinase Inhibitor Treatment in Chronic Myeloid Leukemia - A Prospective Observational Multicenter Study (TAKE-IT)
The Effect of Active Adherence-Encouraging Interventions on Adherence to Tyrosine Kinase Inhibitor Treatment in Chronic Myeloid Leukemia - A Prospective Observational Multicenter Study (TAKE-IT)
Enrollment Status: Completed
Publish Date: June 07, 2017
Intervention Type: Behavioral
Study Phase: Not Applicable
View 1 Less Clinical Trial

41 Total Publications

Response rates of extra-nodal diffuse large B cell lymphoma to anti-CD19-CAR T cells: A real word retrospective multicenter study.
Response rates of extra-nodal diffuse large B cell lymphoma to anti-CD19-CAR T cells: A real word retrospective multicenter study.
Journal: European journal of haematology
Published: January 18, 2023

Areas of Expertise

MediFind evaluates expertise by pulling from factors such as number of articles a doctor has published in medical journals, participation in clinical trials, speaking at industry conferences, prescribing and referral patterns, and strength of connections with other experts in their field.

Learn more about MediFind’s expert tiers

Find Mr. Benyamini's expertise for a condition
ConditionClose
      View All 12 Experienced Conditions
      Want to save this expert for later?
      Sign Up
      Not sure about your diagnosis?
      Check Your Symptoms
       
       
       
       
      Learn about our expert tiers
      Learn More
      Are you the provider on this profile?
      Claim Profile